Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)

This study has been completed.
Sponsor:
Information provided by:
Orasi Medical, Inc.
ClinicalTrials.gov Identifier:
NCT00973518
First received: September 4, 2009
Last updated: August 12, 2010
Last verified: August 2010
  Purpose

The current study is intended to enrich and extend the database of Alzheimer's Disease (AD) and healthy control (HC) MEG scans and will include patients meeting DSM-IV-TR criteria for dementia of Alzheimer's type, and age- and gender-matched HC subjects meeting criteria of normal neurological function. This study will include 2 MEG and electroencephalography (EEG) scans on approximately 80 AD subjects and 80 HC subjects over approximately 30 days. All subjects will have MEG/EEG scans at baseline and 28 - 35 days after baseline. Within one day of each scan visit AD subjects will undergo 4 standard functional tests while HC subjects will undergo 2 standard functional tests.

This study will test the following hypotheses:

  • MEG scans of resting-state, eyes-open brain function reveal patterns of correlated activity that differ between HC subjects and subjects diagnosed with dementia of Alzheimer's type;
  • Patterns of correlated activity measured in AD subjects correspond to other measures of disease severity such as standard functional test scores;
  • MEG scan patterns for HC subjects are consistent across repeated measures taken over a 30 day period.

Condition
Alzheimer's Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction Test: A One-month Study

Resource links provided by NLM:


Further study details as provided by Orasi Medical, Inc.:

Primary Outcome Measures:
  • Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently (e.g. at all evaluation time points) between HC and AD subjects [ Time Frame: approximately 30 days ] [ Designated as safety issue: No ]
  • Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ across time points within single subjects and across groups of HC and AD subjects [ Time Frame: Approximately 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Identification and characterization of Orasi SNI test features that correlate with independent measures of cognitive function based on functional testing (ADAS-Cog sum of boxes, and MMSE raw score, One Card Learning Test) [ Time Frame: Approximately 30 days ] [ Designated as safety issue: No ]
  • Identification and characterization of Orasi SNI test features that correlate with AD medications being taken by AD subjects [ Time Frame: Approximately one month ] [ Designated as safety issue: No ]
  • Identification, characterization and comparison of scan results generated by MEG and EEG [ Time Frame: Approximately one month ] [ Designated as safety issue: No ]

Estimated Enrollment: 160
Study Start Date: September 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Alzheimer's Disease subjects
Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
Healthy Control subjects
Age & gender-matched subjects determined to be healthy.

Detailed Description:

This study is intended to extend the capabilities of the Synchronous Neural Interaction® (SNI) test, which is under development by the sponsor, Orasi Medical, Inc. Magnetoencephalography (MEG) is an FDA-approved, non-invasive technique used to measure magnetic fields generated by small intracellular electrical currents in neurons. The SNI test evaluates brain function and dysfunction by analyzing brief (1 minute) MEG scans and comparing individual scan results to a database of MEG scans and clinical information. Proprietary software algorithms process the data generated by MEG instruments allowing Orasi to use the SNI test for accurate tracking and diagnosis of neurological disorders such as Alzheimer's disease (AD) and Multiple Sclerosis (MS). The current study is intended to enrich and extend the database of AD and healthy control (HC) MEG scans and will include patients meeting DSM-IV-TR criteria for dementia of Alzheimer's type, and age- and gender-matched HC subjects meeting criteria of normal neurological function. This study will include 2 MEG and EEG scans on approximately 80 AD subjects and 80 HC subjects over approximately 30 days. All subjects will have MEG/EEG scans at baseline and 28 - 35 days after baseline. Within one day of each scan visit AD subjects will undergo 4 standard functional tests while HC subjects will undergo 2 standard functional tests. The results generated in this study will be used to improve the accuracy of the SNI test for diagnosing and tracking the progression of AD. Once a robust training set or template is described, Orasi Medical will conduct additional clinical studies to formally test the diagnostic accuracy of the technology and support applications for regulatory approval to market the SNI test for AD. The objective of this work is to produce and validate a novel tracking and diagnostic technology for AD that is more selective and sensitive than currently available diagnostic tools.

  Eligibility

Ages Eligible for Study:   50 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The current study will include patients meeting DSM-IV-TR criteria for dementia of Alzheimer's type, and age- and gender-matched healthy control subjects meeting criteria of normal neurological function.

Criteria

Inclusion Criteria:

  • Subject has been diagnosed with dementia of Alzheimer's type (DSM-IV-TR) or is serving as a healthy control subject with normal neurological function based on medical history and following neurological exam.
  • AD Subject has a screen MMSE raw score > 16 or HC subject has a screen MMSE raw score > 26.
  • Subject is between 50 and 90 years of age at the time of screening.
  • Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
  • Subject is a non-smoker.
  • Subject is judged to be in good health other than AD, based on medical history and brief physical examination.
  • AD subject has a care-giver or spouse who is willing and able to assure subject compliance with study procedures or subject is participating as a healthy control subject.

Exclusion Criteria:

  • Subject has a history or diagnosis of a significant neurological condition other than Alzheimer's disease including Parkinson's disease, vascular dementia, Lewy body dementia, frontal temporal dementia, human immunodeficiency virus, multiple sclerosis, seizures, epilepsy, stroke, ADHD, dyslexia, or severe traumatic brain injury.
  • Subject has a history of primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder.
  • Subject has a Modified Hachinski Ischemia Scale (HIS) score greater than 4.
  • The subject has a recent history (within 2 years) of alcohol or substance abuse/dependence.
  • Subject had an MRI within two weeks prior to Study Day 1.
  • Subject has metal dental braces, pacemaker or other common medical devices that may interfere with the MEG scan.
  • Subject is unable to complete the MEG scan procedure.
  • Investigator has any concern regarding the safe participation of a subject in the study, or if for any other reason the investigator considers the subject inappropriate for study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00973518

Locations
United States, Illinois
Rush Alzheimer's Disease Center
Chicago, Illinois, United States, 60612
Alexian Brothers Neuroscience Institute
Elk Grove Village, Illinois, United States, 60007
Sponsors and Collaborators
Orasi Medical, Inc.
Investigators
Principal Investigator: Concetta Forchetti, MD, PhD Alexian Brothers Neuroscience Institute
Principal Investigator: Raj C Shah, MD Rush Alzheimer's Disease Center
  More Information

No publications provided

Responsible Party: Todd Verdoorn, Ph.D., Chief Scientific Officer, Orasi Medical, Inc.
ClinicalTrials.gov Identifier: NCT00973518     History of Changes
Other Study ID Numbers: ADD 09-02
Study First Received: September 4, 2009
Last Updated: August 12, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Orasi Medical, Inc.:
Alzheimer's Disease
AD
Healthy Control

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on July 24, 2014